Boothbay Fund Management’s Praxis Precision Medicines PRAX Stock Holding History
Bought
Maintained
Sold
Other funds holding PRAX
BBA
Boothbay Fund Management's PRAX Position: Q3 2026 in Review
Boothbay Fund Management sold out of Praxis Precision Medicines (PRAX) in Q3 2026, closing a stake of 17,968 shares — an estimated $5.95M sold.
Boothbay Fund Management first reported a position in PRAX in Q3 2021 and held it in 13 quarters. The position peaked at $6.18M in Q4 2025. 339 funds tracked by Wall St. Rank hold PRAX as of Q3 2026.
- Boothbay Fund Management reported no remaining Praxis Precision Medicines position as of Q3 2026 after selling out during the quarter.
- Boothbay Fund Management sold 17,968 Praxis Precision Medicines shares in Q3 2026, an estimated $5.95M.
- Boothbay Fund Management first reported a position in Praxis Precision Medicines in Q3 2021 and held it in 13 quarters.
- Boothbay Fund Management's Praxis Precision Medicines position peaked at $6.18M in Q4 2025.
- 339 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2026.
Based on Boothbay Fund Management's 13F filing for Q3 2026, filed 16 Nov 2026.